Promega and MyBio Sign Exclusive Distribution Agreement
News Jun 12, 2013
Promega Corporation has announced that it has selected MyBio, Ireland’s leading specialist bioscience reagents supplier, to be its new, exclusive distributor in the Republic of Ireland and Northern Ireland.
From the 9th July 2013 MyBio will provide scientists in Ireland with the complete range of Promega products, combined with on-demand access to expert technical support and resources via MyBio’s on the ground application specialists.
Customers purchasing Promega products through MyBio will also be able to take advantage of Promega’s own technical scientific support services.
Promega chose MyBio to be its new, dedicated partner in Ireland based on MyBio’s reputation for excellence and proven application expertise, as well as the team’s ability to give one-on-one support to customers.
By aligning with MyBio, Promega can build and extend relationships with the exciting life science sector in Ireland, whilst continuing to provide real value to customers across the entire world class product range.
“We are delighted to announce the partnership with MyBio, a company that shares Promega’s vision for product and service excellence,” commented Derek McCall, Managing Director, Promega UK.
McCall continued, “Establishing a dedicated partner in Ireland will ensure customers in the region have easier, faster access to our market leading products with online, on call, on-site support.”
“Promega is recognized globally as a dynamic and engaging brand,” said Linda Nolan PhD, Managing Director, MyBio. “MyBio is a customer-focused, niche, application driven company with a personalized approach to individual research project needs, where scientists can source the latest technologies in scientific reagents with full and competent technical support. Promega’s product range is an excellent fit with both our vision and capabilities.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE